Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

BACKGROUND: Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER(+)) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Breast Cancer Res
Egile Nagusiak: Ribas, Ricardo, Pancholi, Sunil, Rani, Aradhana, Schuster, Eugene, Guest, Stephanie K., Nikitorowicz-Buniak, Joanna, Simigdala, Nikiana, Thornhill, Allan, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dowsett, Mitch, Johnston, Stephen R., Martin, Lesley-Ann
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5992820/
https://ncbi.nlm.nih.gov/pubmed/29880014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-0983-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak